Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

506
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
506
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

291
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
291

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SOPA and SIMPA: normalized single-sample integrated multiomics pathway analysis of tumor heterogeneity in solid cancers.

Briefings in bioinformatics·2026
Same author

Anorectal Disorders: Do not throw the baby out with the dirty water.

Gastroenterology·2026
Same author

From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma.

Frontiers in cellular and infection microbiology·2026
Same author

Safety of Apixaban for Postoperative Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Single-Centre Retrospective Cohort Study.

Obesity surgery·2026
Same author

Efficacy of Fibrin Sealants and Polyglycolic Acid Sheets in Reducing Postoperative Hemorrhage Following Gastric Endoscopic Submucosal Dissection: A Meta-analysis of Randomized and Observational Studies.

Journal of gastrointestinal cancer·2026
Same author

Endoscopic Ultrasound-Guided Gastroenterostomy Versus Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Systematic Review and Meta-Analysis.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2026

Related Experiment Video

Updated: Jan 10, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K

Metabolic Dysfunction-Associated Steatohepatitis in Focus: Pathogenesis, Non-Invasive Diagnostics, and Future

Abdulrahman Ismaiel1, Mhd Bashir Almonajjed2, Cristina Sorina Catana3

  • 1Second Department of Internal Medicine, Iuliu Hatieganu, University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Archives of Medical Research
|November 29, 2025
PubMed
Summary

Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver condition. New non-invasive methods are improving MASH detection and fibrosis assessment, offering hope for better patient outcomes.

Keywords:
DiagnosisLiver fibrosisMashMasldNon-invasive biomarkersPersonalized medicine

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K

Related Experiment Videos

Last Updated: Jan 10, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K

Area of Science:

  • Hepatology and metabolic disease research.
  • Development of advanced diagnostic tools for liver conditions.

Background:

  • Metabolic dysfunction-associated steatohepatitis (MASH) is the advanced stage of metabolic dysfunction-associated steatotic liver disease (MASLD).
  • MASH is linked to obesity, insulin resistance, and metabolic syndrome, posing a significant global health challenge.
  • Current diagnostic methods, including liver biopsy, have limitations, necessitating alternative approaches.

Purpose of the Study:

  • To review the current understanding of MASH pathophysiology.
  • To explore diagnostic challenges and innovative non-invasive strategies for MASH detection and fibrosis evaluation.
  • To highlight the importance of updated criteria and multi-omics approaches for risk stratification.

Main Methods:

  • Review of current literature on MASH pathophysiology and diagnostics.
  • Evaluation of non-invasive diagnostic techniques such as elastography, MRI, and serum biomarkers (e.g., cytokeratin-18, NIS4, FAST scores).
  • Discussion of updated MASLD criteria for improved risk stratification.

Main Results:

  • Non-invasive techniques show promise for detecting MASH and assessing fibrosis severity.
  • Updated MASLD criteria enhance risk stratification, including lean MASH phenotypes.
  • Multi-omics approaches are crucial for future personalized MASH management.

Conclusions:

  • Advancing non-invasive diagnostics is essential for managing the growing burden of MASH.
  • Personalized strategies are needed for early detection, disease halting, and improved patient outcomes.
  • Integrating multi-omics data will refine understanding and treatment of MASH.